Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1986 1
1987 3
1989 1
1990 2
1991 1
1992 3
1993 2
1994 7
1995 4
1996 4
1997 1
1998 1
1999 9
2000 9
2001 9
2002 6
2003 10
2004 10
2005 11
2006 13
2007 6
2008 9
2009 15
2010 31
2011 26
2012 13
2013 8
2014 11
2015 11
2016 13
2017 13
2018 12
2019 14
2020 11
2021 13
Text availability
Article attribute
Article type
Publication date

Search Results

275 results
Results by year
Filters applied: . Clear all
Page 1
Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology.
Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Rudà R, Schlegel U, Siegal T, Soussain C, Abacioglu U, Cassoux N, Deckert M, Dirven CM, Ferreri AJ, Graus F, Henriksson R, Herrlinger U, Taphoorn M, Soffietti R, Weller M; European Association for Neuro-Oncology Task Force on Primary CNS Lymphoma. Hoang-Xuan K, et al. Among authors: schlegel u. Lancet Oncol. 2015 Jul;16(7):e322-32. doi: 10.1016/S1470-2045(15)00076-5. Lancet Oncol. 2015. PMID: 26149884 Free article. Review.
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society. Herrlinger U, et al. Among authors: schlegel u. Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14. Lancet. 2019. PMID: 30782343 Free article. Clinical Trial.
Injuries and overuse syndromes in powerlifting.
Siewe J, Rudat J, Röllinghoff M, Schlegel UJ, Eysel P, Michael JW. Siewe J, et al. Among authors: schlegel uj. Int J Sports Med. 2011 Sep;32(9):703-11. doi: 10.1055/s-0031-1277207. Epub 2011 May 17. Int J Sports Med. 2011. PMID: 21590644
Corticosteroids compromise survival in glioblastoma.
Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell SS, Donnola S, Dai C, Ozawa T, Chang M, Chan TA, Beal K, Bishop AJ, Barker CA, Jones TS, Hentschel B, Gorlia T, Schlegel U, Stupp R, Weller M, Holland EC, Hambardzumyan D. Pitter KL, et al. Among authors: schlegel u. Brain. 2016 May;139(Pt 5):1458-71. doi: 10.1093/brain/aww046. Epub 2016 Mar 28. Brain. 2016. PMID: 27020328 Free PMC article.
The Diagnosis and Treatment of Primary CNS Lymphoma.
von Baumgarten L, Illerhaus G, Korfel A, Schlegel U, Deckert M, Dreyling M. von Baumgarten L, et al. Among authors: schlegel u. Dtsch Arztebl Int. 2018 Jun 22;115(25):419-426. doi: 10.3238/arztebl.2018.0419. Dtsch Arztebl Int. 2018. PMID: 29999484 Free PMC article.
Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design.
Geisler T, Poli S, Meisner C, Schreieck J, Zuern CS, Nägele T, Brachmann J, Jung W, Gahn G, Schmid E, Bäezner H, Keller T, Petzold GC, Schrickel JW, Liman J, Wachter R, Schön F, Schabet M, Lindner A, Ludolph AC, Kimmig H, Jander S, Schlegel U, Gawaz M, Ziemann U. Geisler T, et al. Among authors: schlegel u. Int J Stroke. 2017 Dec;12(9):985-990. doi: 10.1177/1747493016681019. Epub 2016 Nov 23. Int J Stroke. 2017. PMID: 27881833 Clinical Trial.
Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07).
Beier D, Proescholdt M, Reinert C, Pietsch T, Jones DTW, Pfister SM, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs SE, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortmann RD, Bogdahn U, Hau P. Beier D, et al. Among authors: schlegel u. Neuro Oncol. 2018 Feb 19;20(3):400-410. doi: 10.1093/neuonc/nox155. Neuro Oncol. 2018. PMID: 29016837 Free PMC article. Clinical Trial.
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
Weller J, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Hau P, Krex D, Grauer O, Goldbrunner R, Bähr O, Uhl M, Seidel C, Tabatabai G, Brehmer S, Bullinger L, Galldiks N, Schaub C, Kebir S, Stummer W, Simon M, Fimmers R, Coch C, Glas M, Herrlinger U, Schäfer N. Weller J, et al. Among authors: schlegel u. Lancet Oncol. 2019 Oct;20(10):1444-1453. doi: 10.1016/S1470-2045(19)30502-9. Epub 2019 Sep 2. Lancet Oncol. 2019. PMID: 31488360 Clinical Trial.
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W; DIRECTOR Study Group. Weller M, et al. Among authors: schlegel u. Clin Cancer Res. 2015 May 1;21(9):2057-64. doi: 10.1158/1078-0432.CCR-14-2737. Epub 2015 Feb 5. Clin Cancer Res. 2015. PMID: 25655102 Free article. Clinical Trial.
275 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page